Figure 1

Evaluation of the antiviral effects of pGCL-2B in HeLa cells. A HeLa cells were pretreated with pGCL-2B at series of doses and the percent of GFP-expressing cells were counted through fluorescence microscopy after 24 h. The results of three independent experiments are expressed as mean ± standard deviation. B HeLa cells were transfected with pGCL-2B (1.25 μg/well), and the transfection rates were counted at different time points. The results of three independent experiments are expressed as mean ± standard deviation. C HeLa cells were transfected with pGCL-2B (1.25 μg/well) or pGCL-NC or MEM only (V), followed by CVB3 infection (MOI = 0.01). The viral titers were measured at 36, 48, 60, 72 h p.i. using supernatants of cell cultures by plaque-forming analysis and the results of three independent experiments are expressed as mean ± standard deviation. Significant differences between pGCL-2B treated (white bars) and pGCL-NC treated samples (striped bars) are indicated (*: P < 0.05) D HeLa cells were transfected with pGCL-2B at 0.75, 1.25 or 1.75 μg/well, respectively, or pGCL-NC or MEM only (V), followed by CVB3 infection (MOI = 0.01). The viral titers were measured at 48 h p.i. using supernatants of cell cultures by plaque-forming analysis and the results of three independent experiments are expressed as mean ± standard deviation. Significant differences between pGCL-2B treated (white bars) and pGCL-NC treated samples (striped bars) are indicated (*: P < 0.05) E HeLa cells were transfected with pGCL-2B (1.25 μg/well) or pGCL-NC or MEM only (Virus), followed by CVB3 infection (MOI = 0.01). After 48 h, GFP-expressing cells were visualized by fluorescence microscopy. LM: light microscopy, FM: fluorescence microscopy.